Authors:
Timothy E. Ritter, MD – Texas Digestive Disease Consultants, PA, Southlake, TX
Chris Fourment, MD – Texas Digestive Disease Consultants, PA, Southlake, TX
Bitaal Sadiq, BS – Texas Digestive Disease Consultants, PA, Southlake, TX
Claudia P. Schroeder, PharmD, PhD – Healix Infusion Therapy, Sugar Land, TX
Tracy C. Okoro, PharmD – Healix Infusion Therapy, Sugar Land, TX
Lucinda J. Van Anglen, PharmD – Healix Infusion Therapy, Sugar Land, TX
Failure of Vedolizumab as First Line Biologic Does Not Decrease Response Rate of Second Line Therapy
